BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27495775)

  • 1. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
    Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
    Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J; Rotjanapan P; Watcharananan SP
    Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.
    Mehta Steinke SA; Alfares M; Valsamakis A; Shoham S; Arav-Boger R; Lees L; Ostrander D; Forman MS; Shedeck A; Ambinder RF; Jones RJ; Avery RK
    Transpl Infect Dis; 2021 Jun; 23(3):e13521. PubMed ID: 33220125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
    Razonable RR
    Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.
    Pierce B; Richardson CL; Lacloche L; Allen A; Ison MG
    Transpl Infect Dis; 2018 Apr; 20(2):e12852. PubMed ID: 29380479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
    Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
    Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
    Mylonakis E; Kallas WM; Fishman JA
    Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
    Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral combination therapy for cytomegalovirus infection in high-risk infants.
    Vora SB; Brothers AW; Waghmare A; Englund JA
    Antivir Ther; 2018; 23(6):505-511. PubMed ID: 29790481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
    Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.